ライフサイエンスコーパス: beta-cyclodextrin

1 the nanoencapsulation of Danube fish oils in beta-cyclodextrin.

2 aromatic rings of curcumin and the cavity of beta-cyclodextrin.

3 olubility by increasing the concentration of beta-cyclodextrin.

4 after disruption of lipid rafts with methyl-beta-cyclodextrin.

5 cubating neonatal cardiomyocytes with methyl-beta-cyclodextrin.

6 epletion fully reversed the effect of methyl beta-cyclodextrin.

7 an aryl sulfonate to promote inclusion into beta-cyclodextrin.

8 eated with 7KCh solubilized in hydroxypropyl-beta-cyclodextrin.

9 following disruption of caveolae with methyl-beta-cyclodextrin.

10 ter incubating dissociated cells with methyl-beta-cyclodextrin.

11 aft domains, similar to the action of methyl-beta-cyclodextrin.

12 oved from erythrocyte membranes using methyl-beta-cyclodextrin.

13 cholesterol stores were depleted with methyl-beta-cyclodextrin.

14 2 mutant (K44A) or treated cells with methyl-beta-cyclodextrin.

15 er and by cholesterol depletion using methyl-beta-cyclodextrin.

16 molecular adapter heptakis-(6-deoxy-6-amino)-beta-cyclodextrin.

17 e ethyl esters form inclusion complexes with beta-cyclodextrin.

18 ion of new crystalline phases not present in beta-cyclodextrin.

19 g a high-surface-area, mesoporous polymer of beta-cyclodextrin.

20 an be prepared from various omega-3 oils and beta-cyclodextrin.

21 mutiwalled carbon nanotubes assimilated with beta-cyclodextrin.

22 ation of aqueous mixtures of omega-3 oil and beta-cyclodextrin.

23 id rafts, similar to positive control methyl-beta-cyclodextrin.

24 rbed from the film and then solubilized with beta-cyclodextrin.

25 otenoids were complexed with 2-hydroxypropyl-beta-cyclodextrin (2-HPbetaCD) in different mass ratios

26 ted with the sterol acceptor 2-hydroxypropyl-beta-cyclodextrin (2-OHCD) confirmed the release of an a

27 e independent methods: 1) exposure to methyl-beta-cyclodextrin, 2) treatment with the HMG-CoA reducta

28 An acetylated-per-azido-beta-cyclodextrin (4) was reacted with series of alkyne

29 n buffer consisting of 10 mM sulfobutylether-beta-cyclodextrin, 40 mM methyl-beta-cyclodextrin, 5 mM

30 fobutylether-beta-cyclodextrin, 40 mM methyl-beta-cyclodextrin, 5 mM carbonate buffer at pH 10, 5 deg

31 this Akt subspecies was ablated with methyl-beta-cyclodextrin, a cholesterol-binding compound, under

32 Indeed, methyl-beta-cyclodextrin, a cholesterol-sequestering agent that

33 , the mice were treated with 2-hydroxypropyl-beta-cyclodextrin, a drug previously reported to rescue

34 Pretreating neutrophils with methyl-beta-cyclodextrin, a lipid raft-disrupting agent, suppre

35 anges in hysteresis due to interactions with beta-cyclodextrin, a molecule that is known to form stab

36 gradual neurodegeneration, and we reveal how beta-cyclodextrin, a potential therapeutic drug, reverts

37 prevented by treatment with 2-hydroxypropyl-beta-cyclodextrin, a promising therapy currently under c

38 zed following treatment with 2-hydroxypropyl-beta-cyclodextrin, a therapy that reduces pathological f

39 nd xylopyranose oligosaccharides; alpha- and beta-cyclodextrins; a nonreducing tetrasaccharide, stach

40 Methyl-beta-cyclodextrin added apically to (MPK)CCD(14) cells r

41 an those of activated carbons and non-porous beta-cyclodextrin adsorbent materials.

42 Disrupting lipid raft by methyl-beta-cyclodextrin also blocked neurite outgrowth.

43 Pharmacological raft disruption using methyl-beta-cyclodextrin also increased CD44-ezrin coprecipitat

44 ing prompted by cholesterol efflux to methyl-beta-cyclodextrin also was prevented, indicating that PM

45 tion reactions of two structurally different beta-cyclodextrins (AmPrbetaCD and AMBnTbetaCD) in the P

46 their inhibition by cationic aminopropylthio-beta-cyclodextrin, AmPrbetaCD, was studied.

47 Insoluble polymers of beta-cyclodextrin, an inexpensive, sustainably produced

48 Methyl beta-cyclodextrin, an inhibitor of caveola formation, re

49 water (calorimetric effect of 536Jg(-1) for beta-cyclodextrin and 304-422.5Jg(-1) for complexes).

50 d stochastic binding of heptakis-(6-O-sulfo)-beta-cyclodextrin and a nine base pair DNA hairpin molec

51 r reactivity was only moderately affected by beta-cyclodextrin and bovine serum albumin, taken as mod

52 inct binding epitopes are capable of binding beta-cyclodextrin and cucurbit[6/7]uril (CB) simultaneou

53 Using the lipid raft disruptors methyl-beta-cyclodextrin and filipin, we demonstrated that anan

54 lloprotease inhibitor batimastat, and methyl-beta-cyclodextrin and filipin, which block lipid raft fo

55 ies of ferrocene-based guests with CB[7] and beta-cyclodextrin and provide a coherent view of the rol

56 n/activation was also decreased after methyl-beta-cyclodextrin and statin treatment but increased in

57 ts showed a cross-peak between H-3 proton of beta-cyclodextrin and the aromatic rings group of curcum

58 In the presence of the beta-cyclodextrin and/or pyrene-modified beta-cyclodextr

59 pyrene-modified beta-cyclodextrin rings, the beta-cyclodextrin and/or pyrene-modified beta-cyclodextr

60 nzene units leads to the dissociation of the beta-cyclodextrin and/or pyrene-modified beta-cyclodextr

61 through cholesterol-scavenging drugs (methyl-beta-cyclodextrin) and the enzymatic breakdown of sphing

62 acid, sodium dodecyl sulfate, hydroxypropyl-beta-cyclodextrin, and NaCl served as model medium const

63 g superparamagnetic iron oxide nanoparticle, beta-cyclodextrin, and polymerized paclitaxel.

64 Hydroxypropyl-beta-cyclodextrin/ANE (HP-beta-CD/ANE) inclusion complex

65 Chitosan chloride and methyl-beta-cyclodextrins appear therefore suitable to formulat

66 ion of a small molecule, heptakis(6-O-sulfo)-beta-cyclodextrin, are demonstrated.

67 lizing a direct compaction grade powder with beta-cyclodextrin as encapsulating agent.

68 micellar electrokinetic chromatography using beta-cyclodextrin as the chiral selector and sodium taur

69 f curcumin through inclusion complexation by beta-cyclodextrin as well as the topology and geometry o

70 and occupancy of binding sites; (ii) methyl-beta-cyclodextrin, as a FA acceptor, to observe the diss

71 st this model, a BLM A5 analog (CD-BLM) with beta-cyclodextrin attached to its terminal amine was syn

72 S faces, functionalized with a pH-responsive beta-cyclodextrin-based supramolecular nanovalve on the

73 Cyclic oligosaccharide 2-hydroxypropyl-beta-cyclodextrin (BCD) is a compound that solubilizes l

74 2-Hydroxypropyl-beta-cyclodextrin (BCD) prevents HIV-1 and SIV infection

75 the protein human serum albumin (HSA), with beta-cyclodextrin being employed as a solubilizing agent

76 Here, we show that beta cyclodextrins (beta-CDs) bind LBs and protect them

77 ap, 4, that is tethered via amide bonds to a beta-cyclodextrin (beta-CD) and a dodecyl chain was achi

78 on-sensitive host-guest crosslinkers between beta-cyclodextrin (beta-CD) and ferrocene (Fc) and iron

79 f the tricyclic antidepressant doxepin using beta-cyclodextrin (beta-CD) as a buffer additive is inve

80 Here, we show that by attaching beta-cyclodextrin (beta-CD) cavities to reduced graphene

81 t decreases with increasing concentration of beta-cyclodextrin (beta-CD) in an aqueous solution, and

82 with mono-6-deoxy-6-((2-mercaptoethyl)amino)-beta-cyclodextrin (beta-CD) in order to produce a select

83 d ensemble has been developed by introducing beta-cyclodextrin (beta-CD) into polymer-grafted mesopor

84 that has been chemically functionalized with beta-cyclodextrin (beta-CD) is extremely effective in af

85 le of drug delivery based on the function of beta-cyclodextrin (beta-CD) nanovalves that are responsi

86 ized nanoparticles consist of a monolayer of beta-cyclodextrin (beta-CD) rings positioned selectively

87 erry purees through molecular inclusion with beta-cyclodextrin (beta-CD) was assessed.

88 by direct complexation with solid amorphous beta-cyclodextrin (beta-CD) was investigated.

89 The interaction of beta-cyclodextrin (beta-CD) with mixed bilayers composed

90 between rutin and four cyclodextrins, namely beta-cyclodextrin (beta-CD), (2-hydroxypropyl)-alpha-cyc

91 ole (AN) with alpha-cyclodextrin (alpha-CD), beta-cyclodextrin (beta-CD), hydroxypropyl-beta-cyclodex

92 nclusion complexes of 2-nonanone (2-NN) with beta-cyclodextrin (beta-CD), were prepared by a co-preci

93 Here we report a beta-cyclodextrin (beta-CD)-based polymer network with h

94 The beta-cyclodextrin (beta-CD)-cyclic nitrone conjugate, 5-

95 d light-responsive host-guest complexes with beta-cyclodextrin (beta-CD).

96 crocyclic hosts, cucurbit[7]uril (CB[7]) and beta-cyclodextrin (beta-CD).

97 l materials, i.e. brown rice flour (BRF) and beta-cyclodextrin (beta-CD).

98 unds in aqueous solution was investigated at beta-cyclodextrin (beta-CD)/silver nanoparticle (AgNPs)

99 Different wall materials like beta-cyclodextrin (beta-cyd), whey protein isolate (WPI)

100 ptide LyeTxI and association compound LyeTxI/beta-cyclodextrin (betaCD) against multispecies biofilms

101 nd KR12 cationic peptides were prepared with beta-cyclodextrin (betaCD) at 1:1 molar ratios.

102 a-hemolysin (alphaHL) to map the presence of beta-cyclodextrin (betaCD) at a substrate pore opening.

103 isperse amphiphilic oligoethyleneimine (OEI)-beta-cyclodextrin (betaCD) clusters have been prepared,

104 d yellow fluorescent proteins (Fc-YFPs) onto beta-cyclodextrin (betaCD) molecular printboards was cha

105 vailable sport beverage, with and without 2% beta-cyclodextrin (betaCD) under light and darkness cond

106 of orthogonal supramolecular interactions of beta-cyclodextrin (betaCD)-adamantyl (Ad) host-guest and

107 A series of beta-cyclodextrin (betaCD)-scaffolded glycoclusters expo

108 dition of the chiral cosolvating agent (CSA) beta-cyclodextrin (betaCD).

109 nclusion complex of a ferrocenyl substituted beta-cyclodextrin (betaCD).

110 ve bile acid that exhibits strong binding to beta-cyclodextrin (betaCD).

111 Abolishing CEM formation (methyl-beta-cyclodextrin) blocked OxPAPC-mediated Rac1 activati

112 icry of a maltose-binding protein substrate, beta-cyclodextrin, by the Tyr/Ser binary interface.

113 trin (beta-CD)-cyclic nitrone conjugate, 5-N-beta-cyclodextrin-carboxamide-5-methyl-1-pyrroline N-oxi

114 letion of cholesterol from rafts with methyl-beta-cyclodextrin caused a redistribution of TNFR1 to no

115 Cholesterol depletion with beta-cyclodextrin causes a significant down-regulation o

116 characterization of the rosmarinic acid (RA)-beta-cyclodextrin (CD) complex in aqueous solution by (1

117 ed carbonization (TPC) of Cu(2+)- and Fe(3+)-beta-cyclodextrin (CD) complexes, a rapid reduction of C

118 the particles were loaded with cargo, bulky beta-cyclodextrin (CD) molecules were noncovalently asso

119 ndothelial cells were pretreated with methyl-beta-cyclodextrin (CD) or filipin to ablate raft structu

120 phosphate-buffered saline (PBS), 0.1% methyl-beta-cyclodextrin (CD), or CD plus cholesterol (0.1%, CD

121 d three cytotoxic strains-in the presence of beta-cyclodextrin (CD), which disrupts rafts.

122 Dynamin inhibitors, chlorpromazine, methyl-beta-cyclodextrin, chloroquine, and concanamycin A drama

123 , a novel series of multivalent polycationic beta-cyclodextrin "click clusters" with discrete molecul

124 but following cholesterol efflux with methyl-beta-cyclodextrin, clusters containing zona-binding mole

125 arative scale by HPLC, using a permethylated beta-cyclodextrin column.

126 h excess cholesterol by a cholesterol/methyl-beta-cyclodextrin complex, phenocopying SR-BI KO oocytes

127 The formed extract: beta-cyclodextrin complexes and a physical mixture of ex

128 Multivalent host-guest interactions between beta-cyclodextrin-conjugated superparamagnetic iron oxid

129 aterials were creatively designed based on a beta-cyclodextrin core to impart a biocompatible multiva

130 ta-cyclodextrin (RAMEB) and a low methylated-beta-cyclodextrin (CRYSMEB) were investigated in aqueous

131 A single dose of 2-hydroxypropyl-beta-cyclodextrin (CYCLO) administered at 7 days of age

132 2-hydroxypropyl-beta-cyclodextrin (CYCLO), a modifier of cholesterol eff

133 The moisture content of beta-cyclodextrin/Danube fish oils complexes (common bar

134 at disrupting lipid raft formation by methyl-beta-cyclodextrin decreased NO production and apoptosis.

135 sgk1 with the apical surface, whereas methyl-beta-cyclodextrin decreased the association of sgk1 with

136 Here we measured the rate at which methyl-beta-cyclodextrin depletes cholesterol from a supported

137 sulfobutyl ether-beta-cyclodextrin (SCD), a beta-cyclodextrin derivative carrying ionizable groups t

138 dazim using gold nanorods derivatized with a beta-cyclodextrin derivative to bind this fungicide.

139 dical bTbK in complex with captisol (CAP), a beta-cyclodextrin derivative, host-guest assembling offe

140 Cationic beta-cyclodextrin derivatives were recently introduced a

141 Using this method, we determined that methyl-beta-cyclodextrin differentially extracts cholesterol fr

142 m parasites with cholesterol-specific methyl-beta-cyclodextrin disrupts both membrane liquid order an

143 Disruption of lipid rafts with methyl-beta-cyclodextrin disrupts the functional association of

144 Disruption of the membrane with methyl-beta-cyclodextrin dissociates the EGFR/GM3/caveolin-1/CD

145 Polyethyleneimine (PEI), Dimethyl-beta-cyclodextrin (DM-beta-CD) and Chitosan enhanced the

146 We previously reported that methyl-beta-cyclodextrin eliminates caveolae and blocks tumor n

147 ruption by cholesterol depletion with methyl-beta-cyclodextrin eliminates these light rafts.

148 enitrothion inside the cavity of per-6-amino-beta-cyclodextrin:Eu(III) complex.

149 eported for the first time using per-6-amino-beta-cyclodextrin:Eu(III) complex.

150 The per-6-amino-beta-cyclodextrin:Eu(III):pesticide complexes and their

151 ed into these vesicles using a second methyl-beta-cyclodextrin exchange step.

152 Methyl-beta-cyclodextrin extracted OA from individual sites in

153 cholesterol by metabolic depletion or methyl-beta-cyclodextrin extraction was found to both increase

154 e, knockdown of caveolae formation by methyl-beta-cyclodextrin failed to prevent wild-type caveolin-1

155 ar-infrared fluorophores for bioimaging, and beta-cyclodextrins for potential drug delivery.

156 cells (1 mM cholesterol@randomly methylated-beta-cyclodextrin) for transport assays.

157 ent of HSV-1-infected Vero cells with methyl beta-cyclodextrin from 2 to 9 h postentry reduced plaque

158 ic strategy for controlled synthesis of thio-beta-cyclodextrin functionalized graphene/gold nanoparti

159 ultiwalled carbon nanotubes assimilated with beta-cyclodextrin/glassy carbon electrode exhibited cata

160 Methyl beta-cyclodextrin had no effect on Ca(2+) store depletio

161 2-Hydroxypropyl-beta-cyclodextrin had no effect on transcripts of neuron

162 alpha- and beta-cyclodextrins have been used as scaffolds for the s

163 eties) via controlled esterification or with beta-cyclodextrins (host moieties) through amidation.

164 yclodextrin (HP-alpha-CD), (2-hydroxypropyl)-beta-cyclodextrin (HP-beta-CD) and (2-hydroxypropyl)-gam

165 eberry, were spray-dried using hydroxypropyl-beta-cyclodextrin (HP-beta-CD) and inulin (IN).

166 2-Hydroxypropyl-beta-cyclodextrin (HP-beta-CD) has emerged as a promisin

167 tly, the cycloheptaglucoside 2-hydroxypropyl-beta-cyclodextrin (HP-beta-CD) has shown efficacy as a p

168 ffect of a gradient of 0-50 mM hydroxypropyl-beta-cyclodextrin (HP-beta-CD) on the separation of a gr

169 CNS of the npc1(-/-) mouse, 2-hydroxypropyl-beta-cyclodextrin (HP-beta-CD), a compound known to prev

170 , beta-cyclodextrin (beta-CD), hydroxypropyl-beta-cyclodextrin (HP-beta-CD), randomly methylated-beta

171 n with maltodextrin (MD) and 2-hydroxypropyl-beta-cyclodextrin (HPBCD).

172 2-Hydroxypropyl-beta-cyclodextrin (HPbetaCD) is a Food and Drug Administ

173 lation combines this drug with hydroxypropyl-beta-cyclodextrin (HPbetaCD) to improve its solubility a

174 ies reported ototoxicity of 2-hydroxypropyl- beta-cyclodextrin (HPbetaCD), a cholesterol chelator and

175 2-Hydroxy-propyl-beta-cyclodextrin (HPbetaCD), a cholesterol scavenger, i

176 izing agents, in particular, 2-hydroxypropyl-beta-cyclodextrin (HpbetaCD).

177 Furthermore, we utilized 2-hydroxypropyl-beta-cyclodextrin (HPbetaCD, an emerging therapeutic) ad

178 In preclinical testing, 2-hydroxypropyl-beta-cyclodextrins (HPbetaCD) significantly delayed cere

179 Weekly treatment with hydroxypropyl-beta-cyclodextrin (HPCD) beginning at 7 wk reduced hepat

180 contact time, using sequential hydroxypropyl-beta-cyclodextrin (HPCD) extractions in soils amended wi

181 e, the disruption of SM-rich rafts by methyl-beta-cyclodextrin impaired myosin activation and clot re

182 O by forming a stable inclusion complex with beta-cyclodextrin in aqueous media.

183 lowed by CE-LIF using 0.5 mM hydroxyl propyl-beta-cyclodextrin in borate buffer [80 mM, pH 9.3].

184 response to postprandial micelles or methyl-beta-cyclodextrin in cultured enterocytes, and it is req

185 clodextrin is more potent than hydroxypropyl-beta-cyclodextrin in reducing both cholesterol and bis(m

186 ed with addition of a chiral selector (i.e., beta-cyclodextrin) in the running buffer.

187 lic acid (PAA) nanofibres (NF) incorporating beta-cyclodextrin inclusion complex (beta-CD-IC) of quer

188 s of glutathione thiyl radical (GS(*)); (ii) beta-cyclodextrins increase the kinetic stability of the

189 Treatment of cells with methyl-beta-cyclodextrin increased the hydrolysis rate and tota

190 t depleting cellular cholesterol with methyl-beta-cyclodextrin increased the resilience of stromal ce

191 ntain crystalline phases not present in pure beta-cyclodextrin, indicating true complexation.

192 iously described a technique in which methyl-beta-cyclodextrin-induced lipid exchange is used to prep

193 A methyl-beta-cyclodextrin-induced lipid exchange technique was d

194 revealed that the therapeutic drug candidate beta-cyclodextrin induces the subplasmalemmal location o

195 In 3T3L-1 adipocytes, apoAI, HDL, and methyl-beta-cyclodextrin inhibited chemotactic factor expressio

196 traction of membrane cholesterol with methyl-beta-cyclodextrin inhibited infection by virions but had

197 owed that cholesterol depletion using methyl-beta-cyclodextrin inhibited preimplantation development

198 Recent studies have shown that hydroxypropyl-beta-cyclodextrin injections in npc1(-/-) mice are parti

199 beta-cyclodextrin is known to encapsulate pollutants to

200 We demonstrate that methyl-beta-cyclodextrin is more potent than hydroxypropyl-beta

201 Acute exposure of LLC-PK1 cells to methyl beta-cyclodextrin led to parallel decreases in cellular

202 ectivity was exquisitely sensitive to methyl-beta-cyclodextrin (M beta CD) and nystatin, which disrup

203 and the cholesterol-depleting agents methyl beta cyclodextrin (MBCD) and nystatin (Nys), drugs inhib

204 Methyl-beta-cyclodextrin (MBCD) can efficiently capture a wide

205 Among cyclodextrins (CDs), methyl beta cyclodextrin (MbetaCD) is the most efficient to dep

206 with the cholesterol-extracting agent methyl-beta-cyclodextrin (MbetaCD) not only disrupted the DRM l

207 Extraction with methyl-beta-cyclodextrin (MbetaCD) removed pUL37x1/vMIA from ly

208 Treatment of cells with methyl-beta-cyclodextrin (MbetaCD) significantly reduced the DR

209 Using methyl-beta-cyclodextrin (MbetaCD) to deplete membrane choleste

210 he effect of cholesterol depletion by methyl-beta-cyclodextrin (MbetaCD) treatment on influenza virus

211 mediates this signaling specificity, methyl-beta-cyclodextrin (MbetaCD) treatment was used to disrup

212 nsitive to cholesterol depletion with methyl-beta-cyclodextrin (MbetaCD) was detected.

213 The cholesterol depleting agent methyl-beta-cyclodextrin (mbetaCD) was used to disrupt lipid ra

214 agasi promastigotes were treated with methyl-beta-cyclodextrin (MbetaCD), a sterol-chelating reagent,

215 cholesterol levels were reduced using methyl-beta-cyclodextrin (mbetaCD), as confirmed by Amplex Red

216 Methyl-beta-cyclodextrin (MbetaCD), which disassembles caveolae

217 etreatment with lipid raft disruptor (Methyl-beta-cyclodextrin, MbetaCD) and oxidative stress inhibit

218 te depletion of cholesterol with 5 mm methyl-beta-cyclodextrin (MCD) caused a substantial increase in

219 In addition, cholesterol reduction by methyl-beta-cyclodextrin (MCD) disrupted rafts and shifted MOR

220 wn that depletion of cholesterol with methyl-beta-cyclodextrin (MCD) disrupts caveolar microdomains.

221 with the cholesterol depleting agent, methyl-beta-cyclodextrin (MCD), significantly inhibited CNGA3 a

222 with that of a simple sterol carrier, methyl-beta-cyclodextrin (MCD), when STARD4 and MCD were overex

223 is oocytes with cholesterol-depleting methyl-beta-cyclodextrin (MebetaCD) stimulates phosphorylation

224 In parallel, beta-cyclodextrin mediated the NPC1-independent redistri

225 Spherical chitosan chloride and methyl-beta-cyclodextrin microparticles loaded with DFO (DCH an

226 Membrane cholesterol depletion with methyl-beta-cyclodextrin mimicked the effects of AC6 silencing

227 esterol depletion of macrophages with methyl-beta-cyclodextrin normalized FC content between the two

228 The use of dynasore, PitStop2, methyl-beta-cyclodextrin, nystatin, and filipin (specific inhib

229 ever, this trafficking was blocked by methyl-beta-cyclodextrin or by caveolin knockdown.

230 hort-term cholesterol chelation using methyl-beta-cyclodextrin or by stable knockdown of caveolin-1 a

231 Methyl-beta-cyclodextrin or caveolin knockdown significantly in

232 Depletion of cholesterol through methyl-beta-cyclodextrin or cholesterol oxidase abolished the p

233 pted by lipid raft perturbation using methyl-beta-cyclodextrin or cholesterol oxidase.

234 domains by acute exposure of cells to methyl-beta-cyclodextrin or chronic exposure to different stati

235 , but the response was not reduced by methyl-beta-cyclodextrin or CPM antibody.

236 Treatment with either methyl-beta-cyclodextrin or filipin III to disrupt cholesterol-

237 ted by pretreatment of the cells with methyl-beta-cyclodextrin or Filipin III, hence implicating memb

238 ts that deplete membrane cholesterol (methyl-beta-cyclodextrin or lovastatin) disrupted caveolae, att

239 s rescued by cholesterol depletion by methyl-beta-cyclodextrin or mevastatin.

240 Correspondingly, pharmacological (methyl-beta-cyclodextrin) or genetic disruption of caveolae (Ca

241 toxoids or pretreatment of cells with methyl-beta-cyclodextrin) or osmotic protection of target cells

242 ore, cholesterol lowering by statins, methyl-beta-cyclodextrin, or filipin also activates PKA and, co

243 her in vitro, by treatment with 25 mM methyl-beta-cyclodextrin, or in vivo, by subjecting animals to

244 using Cab-O-sil, medium treated with methyl-beta-cyclodextrin, or serum-free medium.

245 Pretreatment of IECs with methyl-beta-cyclodextrin partially blocks OMV-induced host immu

246 io from intact cells does not reflect methyl-beta-cyclodextrin plasma membrane extraction properties.

247 omimetic material, namely, poly(p-phenylene) beta-cyclodextrin poly(ethylene glycol) (PPP-CD-g-PEG) c

248 ch was to evaluate the performance of porous beta-cyclodextrin polymers (P-CDP) as adsorbents of MPs

249 -guest complexes, but until now cross-linked beta-cyclodextrin polymers have had low surface areas an

250 Cholesterol depletion by methyl-beta-cyclodextrin prevented Kit-mediated activation of t

251 er m1 or m3 muscarinic receptors with methyl-beta-cyclodextrin produced a loss of localization of pro

252 inhibit IP(3)Rs negated the effect of methyl-beta-cyclodextrin, providing further support that IP(3)R

253 A pyrene-modified beta-cyclodextrin (pyrenecyclodextrin)-decorated single-

254 tudy we demonstrate that quaternary ammonium beta-cyclodextrin (QABCD) fulfils both of these requirem

255 clodextrin (HP-beta-CD), randomly methylated-beta-cyclodextrin (RAMEB) and a low methylated-beta-cycl

256 ntrasts with the inhibitory effect of methyl-beta-cyclodextrin reported for other P2X subtypes.

257 ected Ae. aegypti cells with 2-hydroxypropyl-beta-cyclodextrin restores dengue replication in Wolbach

258 sterol levels by brief treatment with methyl-beta-cyclodextrin resulted in a 100-fold reduction of th

259 omains by cholesterol extraction with methyl-beta-cyclodextrin resulted in the release of virions wit

260 lesterol depletion and repletion with methyl-beta-cyclodextrin reversibly altered PI4KIIalpha associa

261 the beta-cyclodextrin and/or pyrene-modified beta-cyclodextrin rings from the stalks, thus opening th

262 the beta-cyclodextrin and/or pyrene-modified beta-cyclodextrin rings will thread onto the azobenzene-

263 the beta-cyclodextrin and/or pyrene-modified beta-cyclodextrin rings, the beta-cyclodextrin and/or py

264 Propofol was complexed with sulfobutyl ether-beta-cyclodextrin (SCD), a beta-cyclodextrin derivative

265 on that is palmitoylated and mediates methyl-beta-cyclodextrin-sensitive self-association of purified

266 Inclusion of CHAs with beta-cyclodextrin strongly limited these interactions to

267 tion as does disruption of rafts with methyl-beta-cyclodextrin, suggesting raft exit enables internal

268 mbrane cholesterol is extracted using methyl beta-cyclodextrin, suggesting that lipid raft microdomai

269 ed by the cholesterol-depleting drug, methyl beta-cyclodextrin, suggesting that the physiological fun

270 negatively charged chiral selector, sulfated beta-cyclodextrin (sulfated beta-CD), that migrated away

271 membrane cholesterol by treating with methyl-beta-cyclodextrin suppressed deoxycholic acid (DCA)-indu

272 with the cholesterol chelating agent, methyl-beta-cyclodextrin, that is thought to disrupt lipid raft

273 terol-sequestering drugs nystatin and methyl-beta-cyclodextrin, the dynamin-specific inhibitor dynaso

274 We used methyl beta-cyclodextrin to deplete cholesterol from polymorpho

275 cells co-expressing CPM and B1R with methyl-beta-cyclodextrin to disrupt lipid rafts reduced the B1R

276 have overcome these limitations using methyl-beta-cyclodextrin to solubilize VLCFA for rapid delivery

277 turing strategy in which applying methylated beta-cyclodextrin to the culture medium allows the seque

278 y interaction, exemplified by the binding of beta-cyclodextrin to the primary and secondary binding s

279 t has been synthesized by covalently linking beta-cyclodextrin to the surface of N, S codoped carbon

280 Some cells were incubated with methyl-beta-cyclodextrin (to deplete cholesterol from membranes

281 entration of a cyclodextrin (sulfobutylether-beta-cyclodextrin) to inhibit crystallization over a 48

282 that depleting endogenous 7-DHC with methyl-beta-cyclodextrin treatment enhances Hedgehog activation

283 rose gradient ultracentrifugation and methyl-beta-cyclodextrin treatment that CLEC-2 translocates to

284 creased to approximately 79 pN/mum by methyl-beta-cyclodextrin treatment to sequester membrane choles

285 he assay by differential binding to sulfated-beta-cyclodextrin used as additive to the phosphate buff

286 mplexes between red bell pepper pigments and beta-cyclodextrin using two different procedures (i.e.,

287 th either 3mg/kg allopregnanolone or 20% w/v beta-cyclodextrin vehicle.

288 received daily injections of 2-hydroxypropyl-beta-cyclodextrin vehicle.

289 The mass ratio of extract to beta-cyclodextrin was 1:4.

290 ion of the title compound in the presence of beta-cyclodextrin was examined in different conditions.

291 e cholesterol (cholesterol mixed with methyl-beta-cyclodextrin), we observed an increase in DAT bindi

292 plexes and a physical mixture of extract and beta-cyclodextrin were evaluated by differential scannin

293 Incubation with methyl-beta-cyclodextrin, which disrupts caveolae, or with wort

294 eated with hypertonic medium and with methyl-beta-cyclodextrin, which disrupts lipid rafts.

295 to the ER can be overcome by 2-hydroxypropyl-beta-cyclodextrin, which leads to a marked increase in A

296 uires coadministration with sulphobutylether-beta-cyclodextrin, which may accumulate in patients with

297 Here we crosslink beta-cyclodextrin with rigid aromatic groups, providing

298 ntagonist or disrupting caveolae with methyl-beta-cyclodextrin, with an associated approximately 30%

299 lusion complexes of Vitamin A Palmitate with beta-cyclodextrins, without the use of organic solvents,

300 n was achieved with the expectation that the beta-cyclodextrin would lead to increased reactivity to